Morning Market Losers

dipped 63.97 percent to $2.36 after the company reported results from FLAGSHIP trial with AQX-1125 in chronic obstructive pulmonary disease patients with frequent exacerbations failed to demonstrate efficacy in COPD.

shares fell 21.57 percent to $10.97 after the company lowered its Q1 outlook.

shares slipped 7.14 percent to $29.27 after the company announced its plans to buy

beauty business in a $12.5 billon deal.

shares dropped 6.35 percent to $7.81 after the company priced 3.33 million shares at $7.50 per share.

shares slipped 4.64 percent to $6.16. Kepler Cheuvreux analyst Bernd Laux downgraded the rating on AIXTRON from Hold to Reduce, while reducing the price target from EUR7 to EUR5.